http://www.equities.com/news/headline-story?dt=2013-01-30&val=985096&cat=industrial
By a News Reporter-Staff News Editor at Pharma Business Week — Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the U.S. Army Medical Research and Material Command (USAMRMC) has awarded the Company a $2.67 million research contract to support development of AC105, a propriety magnesium formulation being studied as a treatment for acute spinal cord injury (SCI) (see also Acorda Therapeutics, Inc.)…